Location: Switzerland
Total raised: $186.89K
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.07.2026 | - | $186.89K | Venture Ki... |
Mentions in press and media 5
| Date | Title | Description |
| 08.07.2026 | ALP Bio Secures Key Funding, Revolutionizing Biologic Drug Safety with AI | ALP Bio secured €161K from Venture Kick. The biotech firm revolutionizes biologic drug safety. It tackles immunogenicity, a critical and costly development hurdle. Its innovative platform merges human immune tissue models with advanced arti... |
| 03.07.2026 | ALP Bio raises €161K from Venture Kick to improve the safety of biologic medicines | Swiss biotech startup ALP Bio has secured €161,000 (CHF 150,000) from Venture Kick to support the commercial development of its platform, which helps drug developers identify immune-related risks earlier in the development process. By combi... |
| 03.07.2026 | Techbio company ALP Bio obtains CHF 150,000 from Venture Kick | Biologic drugs, including many therapeutic antibodies, can trigger unwanted immune responses in patients. These reactions can reduce treatment effectiveness, lead to side effects, and contribute to costly failures during clinical developme... |
| 30.04.2026 | ALP Bio AG raises CHF 1.75 million pre-seed to de-risk antibody development | Immunogenicity, including anti-drug antibody (ADA) responses, remains one of the most difficult risks in biologics development. These immune responses can reduce therapeutic efficacy, create safety concerns, and force teams to abandon or r... |
| - | ALP Bio | “Alp Bio – Immunogenicity intelligence, grounded in human biology.” |